|
|
艾卡拉肽市场分析报告
|
Dyax Corp. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis
... develop and commercialize subcutaneous DX-88 (ecallantide) for the treatment of hereditary ... FDA) and is marketed as KALBITOR (ecallantide) for the treatment of acute ... develop and commercialize subcutaneous DX-88 (ecallantide) for the treatment of hereditary ...
Cubist Pharmaceuticals Inc. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis
... Limited. PRODUCT PIPELINE CB-500,929 (ecallantide) The company has obtained a license ... Corp. (Dyax). The company is studying ecallantide initially in the reduction of blood loss ...
Hereditary angioedema – Pipeline Insight, 2020
... in adults 18 years of age and older. Ecallantide (Brand name: Kalbitor) - Manufactured by Dyax ...
Global Hereditary Angioedema Drug Market Growth 2024-2030
... Berinert and the kallikrein inhibitor ecallantide (Kalbitor) for treatment of acute attacks ...
Global Hereditary Angioedema Drug Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030
... Berinert and the kallikrein inhibitor ecallantide (Kalbitor) for treatment of acute attacks ...
Global Hereditary Angioedema Drug Market Research Report 2024(Status and Outlook)
... Berinert and the kallikrein inhibitor ecallantide (Kalbitor) for treatment of acute attacks ...
Hereditary Angioedema Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class (C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, Other Drug Classes), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels), By Application (Prophylaxis, On-demand), By Region and Competition, 2020-2030F
... monoclonal antibodies, such as lanadelumab and ecallantide, have been engineered to specifically inhibit ...
United States Hereditary Angioedema Therapeutics Market By Treatment (C1-esterase inhibitor, Bradykinin B2 receptor antagonist, Kallikrein inhibitor, Others), By Route of Administration (Intravenous, Subcutaneous, Oral), By End-use (Prophylaxis, On-demand) Region and Competition, Forecast and Opportunities, 2019-2029F
... approval of acute treatment options like ecallantide (Kalbitor) and icatibant (Firazyr) has ...
Global Hereditary Angioedema Drug Market Research Report 2024, Forecast to 2032
... Berinert and the kallikrein inhibitor ecallantide (Kalbitor) for treatment of acute attacks ...
Global Hereditary Angioedema Drug Market Research Report 2025(Status and Outlook)
... Berinert and the kallikrein inhibitor ecallantide (Kalbitor) for treatment of acute attacks ...
Hereditary Angioedema Drugs Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type
... , FIRAZYR (icatibant B2 antagonist), and KALBITOR (ecallantide), underscores its leadership, with TAKHZYRO ...
|
|
|
|
